33 posts tagged technology transfer from Commercializing Science.
Faculty-led spinout decks often bury the technical risk that actually determines investability, burying it under market slides nobody asked for.
A. KovacsMost university patent maintenance processes waste money on the wrong assets. Here's why portfolio pruning fails and what a better decision framework looks like.
A. KovacsMost university equity policies in spinouts are structured to deter investors, not attract them. Here's what goes wrong and how to fix it.
A. KovacsMinimum annual royalty clauses are meant to protect universities from dormant licenses, but most are drafted in ways that undermine both parties from the start.
A. KovacsAudit rights in license agreements are among the most valuable and most neglected tools in technology transfer. Here's why that keeps costing universities money.
A. KovacsMost university spinout boards are assembled for optics, not governance. Here's why the wrong structure kills promising companies before they scale.
A. KovacsRoyalty stacking provisions look like licensee protection but often destroy deal economics. Here's what universities get wrong and how to fix it.
A. KovacsCo-invention disputes between universities and industry partners kill deals, poison relationships, and go unresolved for years. Here's why they happen and how to prevent them.
A. KovacsBayh-Dole compliance at most universities is a defensive legal exercise. Here's why that posture quietly destroys commercialization potential.
A. KovacsThe gap between a funded research project and a viable spinout company destroys more potential than bad science ever does. Here's what actually goes wrong.
A. KovacsMost university commercialization readiness reviews are scheduled at the wrong stage, asking the wrong questions, and missing the window where intervention actually changes outcomes.
A. KovacsMost patent claims are drafted to survive examination, not to support licensing deals. Here's what gets lost when prosecution strategy ignores commercial reality.
A. KovacsUniversity patent priority decisions are usually made by administrators, not commercialization strategists, and the timing guarantees bad outcomes. Here's what to fix.
A. KovacsReach-through royalty provisions look like smart IP protection but routinely kill university-industry deals. Here's what to do instead.
A. KovacsMost invention valuation methods in tech transfer generate figures that satisfy spreadsheets but fail negotiations. Here's what actually works.
A. KovacsMost license milestone structures protect universities from inaction but accidentally punish real development progress. Here's what to do instead.
A. KovacsSublicensing provisions in university license agreements often hand control to licensees by default. Here's what to negotiate before it's too late.
A. KovacsMost university patent prosecution focuses on legal coverage, not commercial timing. Here's why that mismatch quietly kills licensing deals before they start.
A. KovacsMost NDAs in university-industry research partnerships are written to protect everyone and end up protecting no one. Here's why, and what to do instead.
A. KovacsMost tech transfer royalty negotiations anchor on industry averages and gut feel. Here's why that produces bad deals and what to use instead.
A. KovacsMTAs look like administrative paperwork, but buried clauses routinely strip universities and startups of the IP rights they need to commercialize research.
A. KovacsField-of-use restrictions in university license agreements promise focused commercialization but routinely strangle deal value and block better applications from reaching market.
A. KovacsVague IP assignment language in sponsored research agreements creates ownership disputes that kill commercialization deals years after the science is done.
A. KovacsExclusive licenses feel like wins for everyone at signing. Here's why they quietly kill commercialization, and what to structure instead.
A. KovacsOption agreements should de-risk early licensing deals, but most TTOs use them wrong. Here's what's broken and how to fix it.
A. KovacsTRL scores feel objective but are routinely gamed or misread. Here's what's really happening and how to use them honestly.
A. KovacsSponsored research agreements shape IP ownership, licensing rights, and spinout potential before a patent is ever filed. Here's what most researchers miss.
A. KovacsProof-of-concept funding is the missing bridge between lab discovery and licensable technology, here's why most institutions underinvest in it.
A. KovacsMost university licensing deals collapse not because of bad science or bad intent, but because of preventable negotiation failures. Here's what actually goes wrong.
A. KovacsMost industry-university partnerships collapse within two years. Here's why most fail and three proven models that deliver results.
A. KovacsMost university spinouts fail because brilliant researchers become accidental executives without proper transition support.
A. KovacsUniversity TTOs focus on licensing revenue and patent counts instead of startup success and economic impact.
A. Kovacs